The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19 x CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, "BiTE") is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.Kompozicija koja sadrži CD19xCD3 bispecifično antitelo za upotrebu prema postupku tretirđnja tumorske mase tkiva limfnog čvora i/ili ekstranodalnog limfoma izazvanog difuznim B krupnoćelijskim limfomom (DLBCL) kod pacijenta, gde postupak dalje sadrži primenu najmanje jednog glukokortikoida.Prijava sadrži još 17 patentnih zahteva.
